FBR Capital Reiterates Outperform on Evoke Pharma (EVOK) Following 2Q Report
Tweet Send to a Friend
FBR Capital reiterated an Outperform rating and $9.00 price target on Evoke Pharma (NASDAQ: EVOK) following the company's 2Q earnings ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
